Oncofetal antigens. Increasing the specificity of the CEA radioimmunoassay.
The biologic and clinical significance of the oncofetal antigens carcinoembryonic antigen (CEA) and alpha1-fetoprotein (AFP) are discussed. Although the current assays for these molecules are not tumor-specific, measurement of these molecules in the circulation of cancer patients is useful either for tumor diagnosis or for management of the cancer patient in the postoperative or post-chemotherapy state. An approach to increasing the specificity of the CEA radioimmunoassay is described.
D000653:Amniotic Fluid / Q000276:immunology; D000818:Animals; D002272:Carcinoembryonic Antigen / Q000032:analysis* / Q000134:cerebrospinal fluid / Q000652:urine; D006528:Carcinoma, Hepatocellular / Q000276:immunology; D002490:Central Nervous System / Q000002:abnormalities; D004064:Digestive System / Q000276:immunology; D005260:Female; D005316:Fetal Distress / Q000276:immunology; D006801:Humans; D007106:Immune Sera; D005779:Immunodiffusion; D007408:Intestinal Absorption; D008113:Liver Neoplasms / Q000276:immunology; D009364:Neoplasm Recurrence, Local / Q000276:immunology; D009369:Neoplasms / Q000175:diagnosis; D010996:Pleural Effusion / Q000276:immunology; D011247:Pregnancy; D011379:Prognosis; D011863:Radioimmunoassay; D000509:alpha-Fetoproteins / Q000032:analysis* / Q000096:biosynthesis / Q000502:physiology
D002272:Carcinoembryonic Antigen; D007106:Immune Sera; D000509:alpha-Fetoproteins